leyuÀÖÓÚ

ÖܾÁÑþ

ְλ/Ö°³Æ

Ò©Àíѧ½ÌÊÚ£¬Ò½Ñ§²©Ê¿£¬²©Ê¿Éúµ¼Ê¦£»

¹ã¶«Ê¡ÄÏÔÁÓÅÐã½Ìʦ£»leyuÀÖÓÚ½ÌѧÃûʦ£»

ÖйúÒ©Àíѧ»áÈ«¹úÀíÊ£¬ÈÙÓþÀíÊ£»ÖйúÒ½Ò©½ÌÓýЭ»áÖÐÒ©¼°Ãñ×åÒ©leyuÀÖÓÚÓëÆÀ¼Û·Ö»á¸±Ö÷ÈÎίԱ£»

¹ã¶«Ê¡Ò©Àíѧ»á¸±Àíʳ¤¡¢³£ÎñÀíÊ£»¹ã¶«Ê¡Ò©Àíѧ»áÖÐÒ©Ò©ÀíרҵίԱ»áÖ÷ÈÎίԱ¡¢ÃûÓþÖ÷ÈÎίԱ£»¹ã¶«Ê¡Ò©Ñ§»áÀÏÄêҩѧרҵίԱ»á¸±Ö÷ÈÎίԱ£»¹ã¶«Ê¡Ò©Àíѧ»á¿ÆѧÆÕ¼°×¨ÒµÎ¯Ô±»á¸±Ö÷ÈÎίԱ£»¹ã¶«Ê¡ÖÐҽҩѧ»áʵÑéÖÐÒ©Ò©ÀíרҵίԱ»á¸±Ö÷ÈÎίԱ£»

Öйúҩѧ»áÀÏÄêҩѧίԱ»á³£ÎñίԱ£»ÖйúÒ©Àíѧ»áÉöÔàÒ©ÀíרҵίԱ»á³£ÎñίԱ£»ÖлªÖÐҽҩѧ»áÖÐҩʵÑéÒ©Àí·Ö»á³£ÎñίԱ£»ÖлªÖÐҽҩѧ»áÖÐÒ©¶¾ÀíѧÓ밲ȫÐÔleyuÀÖÓڷ᳣ֻÎñίԱ¡¢Î¯Ô±£»¹ã¶«Ê¡Ò½Ò©ÆóÒµ¹ÜÀíЭ»áÒ½Ò©³É¹ûת»¯Ó¦Ó÷᳣ֻÎñÀí¡£

½ÌÓý¾­Àú

¡¾1¡¿ 2002/9¨C2005/7£¬ leyuÀÖÓÚ£¬ ÖÐҩѧ£¬ ²©Ê¿

¡¾2¡¿ 1997/9¨C2000/7£¬ leyuÀÖÓÚ£¬ ÖÐÎ÷Ò½½áºÏ»ù´¡£¬ ˶ʿ

¡¾3¡¿ 1990/9¨C1994/7£¬ leyuÀÖÓÚ£¬ ÖÐҩѧ£¬ ѧʿ

¹¤×÷¾­Àú

¡¾1¡¿ 2007/12-ÖÁ½ñ£¬leyuÀÖÓÚ£¬leyuÀÖÓÚ£¬½ÌÊÚ£¬²©µ¼

¡¾2¡¿ 2003/12-2007/11£¬leyuÀÖÓÚ£¬leyuÀÖÓÚ£¬¸±½ÌÊÚ£¬Ë¶µ¼

¡¾3¡¿ 1994/7-2003/11£¬leyuÀÖÓÚ£¬leyuÀÖÓÚ£¬Öú½Ì¡¢½²Ê¦

leyuÀÖÓÚ·½Ïò

leyuÀÖÓÚÁìÓò£ºÉöÔàÒ©Àíѧ¼°ÖÐÒ©Ò©Àíѧ£»ÖÐÒ©ÐÂÒ©leyuÀÖÓÚ¡£

Ö÷ÒªleyuÀÖÓÚ·½Ïò£ºÖÐÒ©¶ÔÉöÔ༲²¡ÖÎÁÆ×÷Óü°Æä·Ö×Ó»úÀí£¨GPCRÁìÓò£©£»ÖÐÒ©ÐÂҩҩЧѧleyuÀÖÓÚ¡£leyuÀÖÓÚ¹¤×÷°üÀ¨£º£¨1£©Õë¶ÔÉöСÇòÉöÑ×½øÐÐÒ©ÀíѧleyuÀÖÓÚ£¬½¨Á¢Á˶¯ÎïIgAÉö²¡¡¢Éö²¡×ÛºÏÕ÷¡¢C-BSA¡¢HeymannµÈÉö²¡Ä£ÐÍ£¬½«ÖÐÒ½Ò©µÄ¡°Ö¤¡±Í¬Î÷Ò½µÄ¡°²¡¡±½áºÏÆðÀ´£¬ÒÔ´ËÆÀ¼ÛÖÐÒ©£¨Üε¤·½¡¢ÕæÎäÌÀ¡¢Éö¸´¿µ¡¢ÈýÒ¶ÈË×ֲݡ¢ÎåÜßÉ¢¡¢°×ÉÖ×ÜÜÕ¡¢µ¤·ÓËáB£©¶ÔÉöÔ༲²¡µÄÁÆЧ£¬ÉîÈë̽ÌÖÖÐÒ©µ¥Ì壨´¨Üºàº¡¢ÇàÝïËØ£©¡¢ÖÐÒ©ÓÐЧ²¿Î»Èº£¨µ¤²ÎÒû£©µÄÖÎÁÆ»úÖÆ£¬ÎªÖÎÁÆÉö²¡ÓÐЧÖÐÒ©µÄÒ©Àí×÷ÓÃleyuÀÖÓڵ춨ÁË»ù´¡£¬¼¼Êõ´¦ÓÚ¹úÄÚÇ°ÑØ¡££¨2£©ÖÐÒ©ÐÂҩҩЧѧleyuÀÖÓÚ£¨ÖÐÒ©ÐÂҩҩЧÆÀ¼Û¼°ÖгÉÒ©¶þ´Î¿ª·¢£©¡£Ã¿ÄêÕÐÊÕ˶ʿ2-3Ãû£¬²©Ê¿1-2Ãû¡£

ÁªÏµ·½Ê½:zhoujiuyao@vip.tom.com

¿ÆÑм°½Ìѧ¿ÎÌâ

¿ÆÑпÎÌ⣺

¡¾1¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬»ùÓÚÉñ¾­õ£°·/S1Pµ÷¿ØÉöС¹ÜÍâÃÚÌå̽ÌÖÕæÎäÌÀ¶ÔÂýÐÔÉö²¡ÇÊÖ¬´úлµÄ×÷ÓûúÖÆ£¬2024/01-2027/12£¬49ÍòÔª£¬£¬ÔÚÑУ¬Ö÷³Ö

¡¾2¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬S1PR4½éµ¼RhoA/ROCKͨ·µ÷¿ØÂýÐÔÉöСÇòÉöÑ×ϵĤϸ°ûÑ×Ö¢µÄ·Ö×Ó»úÖƼ°ÕæÎäÌÀ¶ÔÆä¸ÉÔ¤×÷ÓÃleyuÀÖÓÚ£¬2022/01-2025/12£¬56ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö

¡¾3¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬»ùÓÚÏßÁ£Ìå×ÔÊɵ÷¿ØNLRP3Ñ×֢СÌå»î»¯Ì½ÌÖÕæÎäÌÀÖÎÁÆÂýÐÔÉöСÇòÉöÑ×µÄ×÷ÓûúÖÆ £¬2017/01-2020/12£¬57ÍòÔª£¬Ö÷³Ö

¡¾4¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬C-BSAÉø͸±ÃÉöÑ×Ä£ÐÍ̽ÌÖÎÂÑôÀûË®·¨¶ÔUPPͨ·¼°NF-¦ÊBµÄ¸ÉÔ¤£¬2011/01-2013/12£¬33ÍòÔª£¬Ö÷³Ö

¡¾5¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£º»ùÓÚ5-HTR1B½éµ¼ÏßÁ£ÌåÉúÎïºÏ³É̽ÌÖÕæÎäÌÀÖÎÁÆÉö²¡×ÛºÏÕ÷µÄҩЧÎïÖÊ»ù´¡¼°»úÖÆ£¬2024/01-2026/12£¬15ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö

¡¾6¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÖصãÏîÄ¿£¬»ùÓÚϵͳҩÀíѧ̽ÌÖÕæÎäÌÀÖÎÁÆÂýÐÔÉöСÇòÉöÑ×µÄ×÷ÓûúÖÆ£¬2018/05-2021/04£¬50ÍòÔª£¬Ö÷³Ö

¡¾7¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðίÖصãÏîÄ¿£¬miRNAÓëAQP2¶ÔÉö²¡×ÛºÏÕ÷µ÷¿Ø¼°ÕæÎäÌÀµÄ¸ÉÔ¤leyuÀÖÓÚ£¬2012/01-2014/12£¬30ÍòÔª£¬Ö÷³Ö

¡¾8¡¿ ¹ã¶«Ê¡¿Æ¼¼¼Æ»®ÏîÄ¿£¬Ô´ÓÚ¡¶É˺®ÂÛ¡·¾­·½ÕæÎäÌÀÖÎÁÆÂýÐÔÉöСÇòÉöÑ×µÄÐÂÒ©leyuÀÖÓÚ£¬2015/1-2017/12£¬20ÍòÔª£¬Ö÷³Ö

¡¾9¡¿ ¹ã¶«Ê¡¸ßµÈѧУ¸ß²ã´ÎÈ˲ÅÏîÄ¿£¬»ùÓÚÍøÂçÒ©Àíѧ̽ÌÖÕæÎäÌÀÖÎÁÆÂýÐÔÉöСÇòÉöÑ×µÄmiRNAÍøÂçµ÷¿Ø»úÖÆ£¬2013/04-2016/12£¬25ÍòÔª£¬Ö÷³Ö

¡¾10¡¿ ¸ßµÈѧУ²©Ê¿Ñ§¿ÆµãרÏî¿ÆÑлù½ðÏîÄ¿£¬Î¢Éø¿ØÊÍ°¢Ã¹ËØÓÕ·¢Éö²¡×ÛºÏÕ÷¼°ÕæÎäÌÀ¶ÔÆämiRNA¡¢AQP2µÄµ÷¿Ø£¬2012/01-2015/12£¬12ÍòÔª£¬Ö÷³Ö

¡¾11¡¿ leyuÀÖÓÚ2021Äê¶Èѧ¿ÆЭͬ´´ÐÂÍŶÓÖصãÏîÄ¿£¬»ùÓÚGµ°°×żÁªÊÜÌåleyuÀÖÓÚÖÐÒ½Ò©ÖÎÁÆÂýÐÔÉö²¡µÄÒ©Àíѧ»úÖÆ£¬2021/01-2022/01,50ÍòÔª£¬Ö÷³Ö

¡¾12¡¿ leyuÀÖÓÚÒ»Á÷ѧ¿Æ½¨Éèѧ¿ÆleyuÀÖÓÚÏîÄ¿£¬ÖÐÒ½¾­·½ÖÎÁÆÂýÐÔÉö²¡µÄÎïÖÊ»ù´¡ÓëϵͳҩÀíѧleyuÀÖÓÚ£¬2019/01-2020/12,130ÍòÔª£¬Ö÷³Ö

¡¾13¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬ÌÇÄò²¡Éö²¡ÍâÃÚÌå miRNAs½éµ¼ÄÚÔàÖ¬·¾×éÖ¯¾ÞÊÉϸ°û-ϵĤϸ°û crosstalk Ó°ÏìÉöÔà×ÔÊɹ¦Äܼ°µ¤·ÓËá B µÄ×÷Óã¬2020/01-2023/12 £¬55ÍòÔª£¬²Î¼Ó

¡¾14¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄê»ù½ðÏîÄ¿£¬´ÓNLRP3Ñ×֢СÌå½éµ¼Ï¸°û½¹Íö̽ÌÖ¼±ÐÔÉöËðÉËÏËά»¯½øÕ¹µÄ»úÖƼ°µ¤·ÓËáBµÄ¸ÉÔ¤£¬2019/01-2021/12£¬21ÍòÔª£¬ÔÚÑУ¬²Î¼Ó

¡¾15¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄê»ù½ðÏîÄ¿£¬°×ÉÖ×ÜÜÕ»ùÓÚ JAK/STAT6ͨ·µ÷¿Ø¾ÞÊÉϸ°ûPD-L2±í´ï´Ù½øÀÇ´¯ÐÔÉöÑ×ÃâÒßÄÍÊܵĻúÖÆleyuÀÖÓÚ£¬2019/01-2021/12£¬21ÍòÔª£¬²Î¼Ó

¡¾16¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬Nrf2¶Ô³¦¸ÎÖáÎÈ̬µÄÓ°Ïì¼°²Ø·½¼×¸ÂËÉÌÀµÄ¸ÉÔ¤×÷Óã¬2018/05-2021/04£¬10ÍòÔª£¬²Î¼Ó

¡¾17¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ð£¬»ùÓÚ×ÔÊɵ÷½ÚNLRP3Ñ×֢СÌå̽ÌÖ°ÍÂíͤÖÎÁÆÀ£ÑñÐԽ᳦Ñ×µÄ×÷ÓûúÖÆ£¬10ÍòÔª£¬2018/01-2020/12£¬²Î¼Ó

¡¾18¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ð×ÔÓÉÉêÇëÏîÄ¿£¬¾ÞÊÉϸ°ûͨ¹ýPD1/PD-Ls ͨ·ÓÕµ¼ÀÇ´¯ÐÔÉöÑ× T ϸ°ûÃâÒßÄÍÊܵķÖ×Ó»úÖƼ°°×ÉÖ×ÜÜյĸÉÔ¤×÷ÓÃleyuÀÖÓÚ£¬2018/05-2021/04£¬10ÍòÔª£¬²Î¼Ó

¡¾19¡¿ ¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ð×ÔÓÉÉêÇëÏîÄ¿£¬ÍâÃÚÌå½éµ¼µÄNF-¦ÊB/NLRP3ͨ·¶ÔIgAÉö²¡µÄ×÷ÓûúÖƼ°ÕæÎäÌÀ¸ÉÔ¤×÷Óã¬2018/05-2021/04£¬10ÍòÔª£¬²Î¼Ó

¡¾20¡¿ ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬»ùÓÚmiRNA-145µ÷¿ØϵĤϸ°û×ÔÊÉ̽ÌÖµ¤·ÓËáB¸ÄÉÆÂýÐÔÉöÑ׵ķÖ×Ó»úÖÆ£¬2017/01-2019/12£¬18ÍòÔª£¬²Î¼Ó

¡¾21¡¿ ¹ã¶«Ê¡ÆÕͨ¸ßУʡ¼¶ÖØ´ó¿ÆÑÐÏîÄ¿£¬»ùÓÚÇàÝïËØÃâÒßÒÖÖÆ·¢ÏÖÖÎÁÆIgAÉö²¡ÁªÓÃôÇà­¸´·½µÄÐÂÒ©leyuÀÖÓÚ£¬2017/01-2019/12£¬30ÍòÔª£¬²Î¼Ó

½ÌѧleyuÀÖÓÚÏîÄ¿£º

¡¾1¡¿ ¹ã¶«Ê¡¸ßУ½ÌѧÍŶӽ¨ÉèÏîÄ¿£¨Ê¡¼¶£©£ºÒ©Àíѧ½ÌѧÍŶÓ£¬ 2018£¨Ö÷³Ö£©

¡¾2¡¿ ¹ã¶«Ê¡leyuÀÖÓÚÉúʾ·¶¿Î³Ì½¨ÉèÏîÄ¿£¨Ê¡¼¶£©£º·½Ò©ÊµÑéÉè¼Æ£»2016£¨Ö÷³Ö£©

¡¾3¡¿ ¹ã¶«Ê¡¸ßУ½ÌѧÍŶӽ¨ÉèÏîÄ¿£¨Ð£¼¶£©£ºÒ©Àíѧ½ÌѧÍŶӣ»2014£¨Ö÷³Ö£©

¡¾4¡¿ leyuÀÖÓÚ½ÌѧleyuÀÖÓÚ¿ÎÌ⣬»ùÓÚBlackBoard ÍøÂç½Ìѧƽ̨ÍøÂç½Ìѧʾ·¶¿Î³Ì¡¶Ò©Àíѧ¡·£»2009£¨Ö÷³Ö£©

¡¾5¡¿ leyuÀÖÓÚ½ÌѧÖÊÁ¿¹¤³ÌÏîÄ¿£¨AFD015161Z0746£©£¬»ùÓÚ΢¿ÎµÄÒ©Àíѧ×ÔÖ÷ѧϰģʽ̽Ë÷£»2016£¨ÅÅÐÐ2£©

¡¾6¡¿ leyuÀÖÓÚУ¼¶½Ìѧ¿ÎÌ⣨201420£©£¬·­×ª½ÌѧģʽÔÚÒ©Àíѧ½ÌѧÖеÄÓ¦ÓÃleyuÀÖÓÚ£»2015£¨ÅÅÃû2£©

¡¾7¡¿ leyuÀÖÓÚ½ÌѧleyuÀÖÓÚ¿ÎÌ⣬½¥½øÐÔ̽Ë÷ÐÔÒ©ÀíѧʵÑéÐÔ½ÌѧleyuÀÖÓÚ£»2010£¨ÅÅÃû2£©

¡¾8¡¿ leyuÀÖÓÚ½ÌÓýleyuÀÖÓÚ¿ÎÌ⣬ҩÀíѧ²¡Àý½ÌѧËزĿâµÄ½¨É裻2008£¨ÅÅÃû4£©

³Ðµ£µÄ¿Î³Ì

¡¾1¡¿ Ò©Àíѧ£ºÖÐҩѧ¡¢Ò©Ñ§¡¢ÖÐҽѧ¡¢ÖÐÎ÷Ò½½áºÏµÈרҵ±¾¿ÆÉú¿Î³Ì£»

¡¾2¡¿ ·½Ò©ÊµÑéÉè¼Æ£ºÒ©Ñ§¡¢ÖÐҩѧ˶ʿ¡¢²©Ê¿leyuÀÖÓÚÉúѧλ¿Î³Ì£»

¡¾3¡¿ ÏÖ´úÖÐÒ©Ò©Àíѧ£ºÒ©Ñ§¡¢ÖÐҩѧleyuÀÖÓÚÉúѧλרҵ¿Î³Ì£»

´ú±íÐԳɼ¨

Ö÷±à»ò²Î±à½Ì²Ä¼°Öø×÷£º

¡¾1¡¿ ÖܾÁÑþ£¬Ö÷±à£¬È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀàרҵµÚÈýÂֹ滮½Ì²Ä¡¢È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀàרҵ¡°Ê®ËÄÎ塱¹æ»®½Ì²Ä£ºÒ©Àíѧ£¨µÚ3°æ£©978-7-5214-3975-5£»ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2024.01£¬

¡¾2¡¿ ÖܾÁÑþ£¬Ö÷±à£¬È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀàרҵµÚÈýÂֹ滮½Ì²Ä¡¢È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀàרҵ¡°Ê®ËÄÎ塱¹æ»®½Ì²Ä£ºÒ©ÀíѧʵÑ飨µÚ3°æ£©978-7-5214-3976-2ÖйúÒ½Ò©¿Æ¼¼³ö°æÉç; 2024.01£¬

¡¾3¡¿ ÖܾÁÑþ£¬Ö÷±à£¬È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀàרҵµÚÈýÂֹ滮½Ì²Ä¡¢È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀàרҵ¡°Ê®ËÄÎ塱¹æ»®½Ì²Ä£ºÒ©Àíѧ˼άµ¼Í¼Óëѧϰָµ¼978-7-5214-3972-4ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2024.08;

¡¾4¡¿ ÖܾÁÑþ£¬Ö÷±à£¬¡¶Ò©Àíѧ¡·Ë«Óï½Ì²Ä£¬È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУÖÐҩѧÀàרҵ˫Óï¹æ»®½Ì²ÄISBN:978-7-5214-1880-4£¬ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2020.07£¬

¡¾5¡¿ ÖܾÁÑþ£¬Ö÷±à.¡¶Ò©Àíѧ¡·£¨µÚ 4 °æ£©£¬¹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»á¡° Ê®ËÄÎ塱 ¹æ»®½Ì²Ä£¬È«¹ú¸ßµÈÖÐÒ½Ò©½ÌÓý½Ì²ÄISBN£º9787117316033£¬ÈËÃñÎÀÉú³ö°æÉ磬2021.09 £»

¡¾6¡¿ ÖܾÁÑþ£¬Ö÷±à£¬¡¶Öйúҽѧ¿¼ÊÔÌâ¿â:ÖÐҽѧÌâ¿â-Ò©Àíѧѧ¿Æ¡·£¬978-7-89456-791-8£¬ÈËÃñÎÀÉú³ö°æÉ磬2019

¡¾7¡¿ ÖܾÁÑþ£¬ ¡°Ê®ËÄÎ塱ÆÕÆÕͨ¸ßµÈ½ÌÓýÖÐҽҩϵÁй滮½Ì²Ä£¬È«¹úÆÕͨ¸ßµÈԺУÖÐҩѧ½Ì²ÄÖ¸µ¼Î¯Ô±»á¸±Ö÷ÈÎίԱ£¨ÏµÁн̲ġ¶ÖÐÒ©Ò©Àíѧ¡·¸±Ö÷±à£©£¬¿Æѧ³ö°æÉç2021,

¡¾8¡¿ ÖܾÁÑþ£¬Ö÷±à.¡¶Ò©Àíѧ¡·£¨µÚ 2 °æ£©£¬È«¹ú¸ßµÈÖÐҽҩԺУҩѧÀàרҵ¡°Ê®ÈýÎ塱 ¹æ»®½Ì²Ä£¬ISBN£º9787521402506ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2018.08,

¡¾9¡¿ ÖܾÁÑþ£¬Ö÷±à.¡¶Ò©ÀíѧʵÑé¡·£¨µÚ2°æ£©£¬È«¹ú¸ßµÈÖÐҽҩԺУҩѧÀàרҵ¡°Ê®ÈýÎ塱¹æ»®½Ì²Ä£¬ISBN 9787521402490ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2018.08

¡¾10¡¿ ÖܾÁÑþ,Ö÷±à.¡¶Ò©Àíѧ˼άµ¼Í¼Óëѧϰָµ¼¡·£¬È«¹ú¸ßµÈÖÐҽҩԺУҩѧÀàרҵ¡°Ê®ÈýÎ塱¹æ»®½Ì²Ä£¬ISBN 9787521403480£¬ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2018.08

¡¾11¡¿ ÖܾÁÑþ,Ö÷±à.¡¶Ò©Àíѧ¡·µÚ 3 °æ£¬È«¹ú¸ßµÈÖÐҽҩԺУҽѧÀà¡° Ê®ÈýÎ塱 ¹æ»®½Ì²Ä£¬ISBN 978-7-117-22494-9. [M].±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬2016

¡¾12¡¿ ÖܾÁÑþ,±àί.¡¶ÖÐҩҩЧleyuÀÖÓÚ·½·¨Ñ§¡·ISBN 978-7-117-22052-1. [M].±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬2016

¡¾13¡¿ ÖܾÁÑþ,Ö÷±à.¡¶Ò©ÀíѧʵÑé¡·È«¹ú¸ßµÈÖÐҽҩԺУҩѧÀà¡° Ê®¶þÎ塱 ¹æ»®½Ì²Ä£¬ISBN 978-7-5067-6829-0. [M].±±¾©£ºÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2015.1

¡¾14¡¿ ÖܾÁÑþ,Ö÷±à.¡¶Ò©Àíѧ¡·È«¹úÆÕͨ¸ßµÈÖÐҽҩԺУҩѧÀà¡°Ê®¶þÎ塱¹æ»®½Ì²Ä£¬ISBN 978-7-5067-6830-6. [M].±±¾©£ºÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2014.8

¡¾15¡¿ ÖܾÁÑþ,Ö÷±à.¡¶Ò©ÀíѧʵÑéÖ¸µ¼¡·ISBN£º978-7-03-035058-9. [M]. ±±¾©£º¿Æѧ³ö°æÉ磬2012

¡¾16¡¿ ÖܾÁÑþ£¬¸±Ö÷±à£¬ÖйúÖгÉÒ©Ãû·½Ò©Ð§ÓëÓ¦ÓôÔÊ飬ÄÚ·ÖÃÚ´úл¡¢·çʪÃâÒß¡¢ÃÚÄòÄÐÉúÖ³¾í£¬ISBN 978-7-03-066635-2£¬¿Æѧ³ö°æÉç,2021£¬

¡¾17¡¿ ÖܾÁÑþ,Ö÷É󣬳£¼û¼²²¡ÓÃÒ©ÊֲᣬISBN 978-7-5359-6941-5£¬¹ã¶«¿Æ¼¼³ö°æÉ磬2021.12£¬

¡¾18¡¿ ÖܾÁÑþ£¬±àί£¬ÉöÔàÒ©Àíѧ£¬£¬ISBN 978-7-117-33808-0-2[M].±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬2024.06

½Ìѧ½±Àø£º

¡¾1¡¿ ÖܾÁÑþ£¨¸ºÔðÈË£©£º2023£¬¹ú¼Ò¼¶±¾¿ÆÒ»Á÷¿Î³Ì-ÏßÏÂÒ»Á÷¿Î³Ì¡¶Ò©Àíѧ¡·

¡¾2¡¿ ÖܾÁÑþ£¨ÅÅÐеÚ2£©£º 2023£¬¹ã¶«Ê¡±¾¿Æ¿Î³ÌÏßÉÏÒ»Á÷¿Î³Ì ¡¶Ò©Àíѧ¡·

¡¾3¡¿ ÖܾÁÑþ£¨¸ºÔðÈË£©£º 2020£¬¹ã¶«Ê¡±¾¿Æ¿Î³ÌÏßÏÂÒ»Á÷¿Î³Ì ¡¶Ò©Àíѧ¡·£»

¡¾4¡¿ ÖܾÁÑþ£¨¸ºÔðÈË£©£º2020£¬¹ã¶«Ê¡±¾¿Æ¸ßУ¿Î³Ì˼Õþʾ·¶ÍŶÓ-Ò©Àíѧ½ÌѧÍŶӣ»

¡¾5¡¿ ÖܾÁÑþ£¬2021,,¹ã¶«Ê¡ÄÏÔÁÓÅÐã½Ìʦ

¡¾6¡¿ ÖܾÁÑþ£¨ÅÅÃûµÚ1£©£ºleyuÀÖÓÚ 2019 Äê½Ìѧ³É¹û¶þµÈ½±£ºÖÐÎ÷Ò½²¢Öر³¾°ÏÂÒ©Àí[5]ѧ¿Î³ÌÁ¢Ì廯½ÌѧģʽµÄ¸Ä¸ïÓëʵ¼ù£»

¡¾7¡¿ ÖܾÁÑþ£¨ÅÅÃûµÚ1£©£»leyuÀÖÓÚ 2017 Äê½Ìѧ³É¹û¶þµÈ½±£ºÒÔÖÐÒ½Ò©ÌØÉ«leyuÀÖÓÚÐÔѧϰģʽΪµ¼ÏòµÄÒ©Àíѧ¿Î³Ì½¨ÉèÓëʵ¼ù£º

¡¾8¡¿ ÖܾÁÑþ£¨ÅÅÃûµÚ1£©£º2016£¬Ò©Àíѧ½ÌÑÐÊÒ±»ÆÀΪleyuÀÖÓÚÏȽø½Ìѧ¹¤×÷»ù²ãµ¥Î»

¡¾9¡¿ ÖܾÁÑþ£¬2016,leyuÀÖÓÚУ¼¶½ÌѧÃûʦ

¡¾10¡¿ ÖܾÁÑþ£¬2012£¬leyuÀÖÓÚµÚÊ®Îå½ìÐÂÄÏ·½½Ìѧ½±Àø»ù½ð¡°ÐÂÄÏ·½ÓÅÐã½Ìʦ¡±

¡¾11¡¿ ÖܾÁÑþ£¬2012£¬¹ã¶«Ê¡¸ßµÈѧУ¡°Ç§°ÙÊ®¹¤³Ì¡±µÚÆßÅúÊ¡¼¶ÅàÑø¶ÔÏó

¡¾12¡¿ ÖܾÁÑþ£¬2011£¬leyuÀÖÓÚÓÅÐã½Ìʦ½±

¡¾13¡¿ ÖܾÁÑþ£¬2009£¬leyuÀÖÓÚ¡°Ê¦µÂ±ê±ø¡±

¡¾14¡¿ ÖܾÁÑþ, 2020£¬¹ã¶«Ê¡±¾¿Æ¸ßУÔÚÏß¿ª·Å¿Î³Ì´óÈü-ÒßÇéÆÚ¼äÔÚÏßÓÅÐã°¸ÀýÆÀ±È½Ìʦ/¿Î³ÌÀࣩ£ºÒ©Àíѧ(¶þµÈ½±)

¡¾15¡¿ ÖܾÁÑþ£¨Ö÷³Ö£©£¬2003£¬¡¶Ò©Àíѧ¡·¿Î³Ì±»ÆÀΪleyuÀÖÓÚУ¼¶Öصã¿Î³Ì

´ú±íÐÔÂÛÎÄÂÛÖø

¡¾1¡¿ Guo L, Zhang Y, Fang G, Tie L, Zhuang Y, Xue C, Liu Q, Zhang M, Zhu K, You C, Xu P, Yuan Q, Zhang C, Liu L, Rong N, Peng S, Liu Y, Wang C, Luo X, Lv Z, Kang D, Yu X, Zhang C, Jiang Y, Dong X, Jiuyao Zhou£¨²¢ÁÐͨѶ£©, Liu Z, Yang F, Eric Xu H,Jin-Peng Sun. Ligand recognition and G protein coupling of the human itch receptor MRGPRX1[J]. Nature Communications, 2023, 14(1): 5004.

¡¾2¡¿ Yuan S, Chen J, Cao Y, Zhao H, Lin S, Xiong J, Xian J, Zhao M, Zhou Y, Zhou J. Investigation of bioactive components and metabolic pathways of Zhen-wu-tang in rat plasma and renal tissue by UPLC-Q-TOF/MS. 1-22, Phytochem Anal. 2024 Sep 24.

¡¾3¡¿ Cao Y, Xiong J, Guan X, Yin S, Chen J, Yuan S, Liu H, Lin S, Zhou Y, Qiu J, Wang D, Liu B, Jiuyao Zhou£¨²¢ÁÐͨѶ£©. Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy[J]. Phytomedicine, 2023, 116: 154901.

¡¾4¡¿ Yuan S, Cao Y, Jiang J, Chen J, Huang X, Li X, Zhou J, Zhou Y, Zhou J£¨Í¨Ñ¶£©. Xuebijing injection and its bioactive components alleviate nephrotic syndrome by inhibiting podocyte inflammatory injury. 196, Eur J Pharm Sci. 2024 May 1.

¡¾5¡¿ ׯîÚÃú,¹ùè´è´,·½¹úÐË,ÂÞÐÀ,Éò˼Դ,Ñî·«,ÖܾÁÑþ£¨Í¨Ñ¶£©. ÀûÓÃÄÉÃ×Ó«¹âËØø¿ìËÙÔ¤²âGµ°°×żÁªÊÜÌå½á¹¹[J]. ҩѧѧ±¨,2023,58(05):1267-1274.

¡¾6¡¿ Bihao Liu, Yiwen Cao, Dejuan Wang, Yuan Zhou, Peichun Zhang , Junbiao Wu, Junqi Chen , Jianguang Qiu, Jiuyao Zhou. Zhen-wu-tang Induced Mitophagy to Protect Mitochondrial Function in Chronic Glomerulonephritis via PI3K/AKT/mTOR and AMPK Pathway£¬Frontiers in Pharmacology, 2021, 12.

¡¾7¡¿ Ruirui Lu, Xu Yan, Guoxing Fang , Yuming Zhuang , Lulu Guo, Chao Zhang, Xiang Wu, Peng Xiao , Yiwen Cao , Fan Yang, Xiao Yu, Jin-peng Sun, Jiu-yao Zhou. A molecular mechanism of UDCA engagement with GPBAR and subsequent G protein interaction revealed by scattered alanine scanning. Biochemical and biophysical research communications, 2022;600:14-21

¡¾8¡¿ Bihao Liu, Jin Lin, Lixia Bai, Yuan Zhou, Ruirui Lu, Peichun Zhang, Dandan Chen,Honglian Li, Jianping Song, Xusheng Liu, Yifan Wu, Junbiao Wu, Chunling Liang,Jiuyao Zhou*. Paeoniflorin Inhibits Mesangial Cell Proliferation and Inflammatory Response in Rats With Mesangial Proliferative Glomerulonephritis Through PI3K/AKT/GSK-3¦Â Pathway[J]. Frontiers in Pharmacology,2019,10.

¡¾9¡¿ Bai Lixia,Li Jicheng,Li Honglian,Song Jianping,Zhou Yuan,Lu Ruirui,Liu Bihao,Pang Yu,Zhang Peichun,Chen Junqi,Liu Xusheng,Wu Junbiao,Liang Chunling,Zhou Jiuyao*. Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-¦ÊB signaling and NLRP3 inflammasome activation by exosomes in rats.[J]. Pubmed,2019,169.

¡¾10¡¿ Yu He£¬Ruirui Lu£¬Junbiao Wu£¬ Yu Pang£¬Jicheng Li£¬ Junqi Chen£¬Bihao Liu£¬ Yuan Zhou*£¬Jiuyao Zhou*. Salvianolic acid B attenuates epithelial-mesenchymal transition in renal fibrosis rats through activating Sirt1-mediated autophagy. Biomed Pharmacother. 2020 Aug;128:110241. doi: 10.1016/j.biopha.2020.110241.Epub 2020 May 22.

¡¾11¡¿ Ruirui Lu, Junqi Chen, Bihao Liu, Hua Lin, Lixia Bai, Peichun Zhang, Dandan Chen, Honglian Li, Jicheng Li, Yu Pang, Yuan Zhou, Jiuyao Zhou*, Junbiao Wu*. Protective role of Astragaloside IV in chronic glomerulonephritis by activating autophagy through PI3K/AKT/AS160 pathway. Phytother Res. 2020 Dec;34(12):3236-3248. doi: 10.1002/ptr.6772. Epub 2020 Jul 29.

¡¾12¡¿ Honglian Li, Ruirui Lu, Yu Pang, Jicheng Li, Yiwen Cao, Hongxin Fu, Guoxing Fang, Qiuhe Chen, Bihao Liu, Junbiao Wu, Yuan Zhou, Jiuyao Zhou. Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF-¦ÊB/NLRP3 Pathway. Front Pharmacol. 2020 Jul 16;11:1080.  doi: 10.3389/fphar.2020.01080.

¡¾13¡¿ Yu Pang, Pei-Chun Zhang, Rui-Rui Lu, Hong-Lian Li, Ji-Cheng Li, Hong-Xin Fu, Yi-Wen Cao, Guo-Xing Fang, Bi-Hao Liu, Jun-Biao Wu, Jiu-Yao Zhou*, Yuan Zhou*. Andrade-Oliveira Salvianolic Acid B Modulates Caspase-1-Mediated Pyroptosis in Renal Ischemia-Reperfusion Injury via Nrf2 Pathway. Front Pharmacol. 2020 Sep 3;11:541426. doi: 10.3389/fphar.2020.541426

¡¾14¡¿ Jicheng Li£¬Yiwen Cao£¬ Ruirui Lu£¬ Honglian Li£¬Yu Pang£¬Hongxin Fu£¬Guoxing Fang£¬Qiuhe Chen£¬Bihao Liu£¬Junbiao Wu£¬Yuan Zhou£¬Jiuyao Zhou, Integrated fecal microbiome and serum metabolomics analysis reveals abnormal changes in rats with Immunoglobulin A nephropathy and the intervention effect of Zhen Wu Tang. Front Pharmacol. 2020 Dec.

¡¾15¡¿ Liu Bihao, Lu Ruirui, Li Honglian, Zhou Yuan, Zhang Peichun, Bai Lixia, Chen Dandan, Chen Junqi, Li Jicheng, Pang Yu, Wu Junbiao, Liang Chunling, Song Jianping, Liu Xusheng, Zhou Jiuyao*, Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-¦ÊB pathway and NLRP3 inflammasome[J].Phytomedicine,2019,59.

¡¾16¡¿ ÀîºìÁ«,ÖܽÛ,ÁÖ»ª,¬ÈðÈð,Áõ±ÌºÃ,³Â¿¡÷è,ÖÜÔ°,ÖܾÁÑþ,Îâ¿¡±ê*.µ¤·ÓËáBͨ¹ý¿¹Ñס¢¿¹Ñõ»¯ºÍ´Ù½ø×ÔÊɼõÇáÂýÐÔÉöСÇòÉöÑ×µÄÉö¹¦ÄÜËðÉË[J].ÖÐÒ©Ò©ÀíÓëÁÙ´²,2019,35(05):34-38.

¡¾17¡¿ ÁÖ¾¢,Å·Ñô»Ô,Áº´ºÁá,ÕÔÕ䶫,ÏÄÀè,ÍôС¸ù,ÖܾÁÑþ*.°×ÉÖ×ÜÜÕ¶ÔĤÐÔÉö²¡´óÊóÉöÔà±£»¤×÷Óü°×ÔÊɵÄÓ°Ïì[J].ÖÐÒ©ÐÂÒ©ÓëÁÙ´²Ò©Àí,2019,30(09):1025-1031.

¡¾18¡¿ Liang Chun-Ling, Zhang Pei-Chun, Wu Jun-Biao, Liu Bi-Hao, Yu-He, Lu Rui-Rui, Jie-Zhou, Zhou Jiu-Yao*. Zhen-wu-tang attenuates Adriamycin-induced nephropathy via regulating AQP2 and miR-92b.[J]. Biomedicine & pharmacotherapy,2019,109.

¡¾19¡¿ Wu Junbiao,He Yu,Luo Yining,Zhang Lei,Lin Hua,Liu Xusheng,Liu Bihao,Liang Chunling,Zhou Yuan,Zhou Jiuyao*. MiR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16.[J]. Journal of cellular physiology,2018,233(4).

¡¾20¡¿ Bihao Liu, Yu He, Ruirui Lu, Jie Zhou, Lixia Bai, Peichun Zhang, Shufang Ye, Junbiao Wu, Chungling Liang, Yuan Zhou, Jiuyao Zhou*. Zhen-wu-tang protects against podocyte injury in rats with IgA nephropathyvia PPAR¦Ã/NF-¦ÊB pathway[J].Biomedicine & Pharmacotherapy, 2018 (101) 635¨C647

¡¾21¡¿ Liang Chun-Ling,Zhang Pei-Chun,Wu Jun-Biao,Liu Bi-Hao,Yu-He,Lu Rui-Rui,Jie-Zhou,Zhou Jiu-Yao*. Zhen-wu-tang attenuates Adriamycin-induced nephropathy via regulating AQP2 and miR-92b.[J]. Pubmed,2019,109.

¡¾22¡¿ Å·Ñô»Ô,³ó°²,ÁÖ¾¢,ÑÏÓÀÍú,ÖܾÁÑþ*.µ¤·ÓËáB¶ÔÉö²¡×ÛºÏÕ÷´óÊóµÄ¸ÄÉÆ×÷ÓÃ[J].Öйúҩʦ,2018,21(08):1339-1342.

¡¾23¡¿ ºØÓê,Îâ¿¡±ê,Ф²©ÔÊ,ÖÜÔ°,ÁÖ»ª,ÂÞܲÄÝ,Áõ±ÌºÃ,ÍõÁÕ,¬ÈðÈð,ÖܽÛ,ÁÖ¾¢,ÖܾÁÑþ*.Üε¤·½¶Ô5/6ÉöÇгýËùÖÂÂýÐÔÉöË¥½ß´óÊóµÄ±£»¤×÷Óü°»úÖÆ[J].ÖÐÒ©ÐÂÒ©ÓëÁÙ´²Ò©Àí,2018,29(04):393-398.

¡¾24¡¿ Ruirui Lu, Jie Zhou, Bihao Liu, Ning Liang, Yu He, Lixia Bai, Peichun Zhang, Yanchun Zhong, Yuan Zhou*, Jiuyao Zhou*. Paeoniflorin ameliorates Adriamycin-induced nephrotic syndrome through the PPAR¦Ã/ANGPTL4 pathway in vivo and vitro[J]. Biomedicine & Pharmacotherapy, 2017 (96)137¨C147.

¡¾25¡¿ WU Jun-biao,ZHOU Yuan,LIANG Chun-ling,ZHANG Xiao-jun,LAI Jie-mei,YE Shu-fang,OUYANG Hui,LIN Jin,ZHOU Jiu-yao*.Cyclovirobuxinum D Alleviates Cardiac Hypertrophy in Hyperthyroid Rats by Preventing Apoptosis of Cardiac Cells and Inhibiting the p38 Mitogen-Activated Protein Kinase Signaling Pathway[J].Chinese Journal of Integrative Medicine,2017,23(10):770-778.